Epigallocatechin gallate nanodelivery systems for cancer therapy

Nutrients

Volumn 8, Issue 5, 2016, Pages

  Granja, Andreia ^a   Pinheiro, Marina ^a   Reis, Salette ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anti cancer therapy; Cancer; EGCG; Green tea; Nanochemoprevention; Nanotechnology

Indexed keywords

CHITOSAN; EPIGALLOCATECHIN GALLATE; GOLD NANOPARTICLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; TELOMERASE; ANTINEOPLASTIC AGENT; CATECHIN; DRUG CARRIER;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CHEMOPROPHYLAXIS; DNA DAMAGE; DNA METHYLATION; GENE EXPRESSION; HUMAN; META ANALYSIS (TOPIC); METASTASIS; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHASE 2 CLINICAL TRIAL; PROTEIN BINDING; REVIEW; TEA; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CATECHIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84969611196     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8050307     Document Type: Review

References (146)

1. Cancer Facts & Figures 2016. American Cancer Society. Available online: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2016/ (accessed on 7 February 2016).
2. Stewart, B.W.; Wild, C.P. World Cancer Report 2014. International Agency for Research on Cancer; World Health Organization: Geneva, Swizerland, 2014.
3. Worldwide Cancer Statistics. Cancer Research UK. Available online: http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer#heading-Zero (accessed on 20 January 2016).
4. CDC-Global Cancer Statistics. Available online: http://www.cdc.gov/cancer/international/statistics.htm (accessed on 21 January 2016).
5. Shafiei, S.S.; Solati-Hashjin, M.; Samadikuchaksaraei, A.; Kalantarinejad, R.; Asadi-Eydivand, M.; Abu Osman, N.A. Epigallocatechin gallate/layered double hydroxide nanohybrids: Preparation, characterization, and In vitro anti-tumor study. PLoS ONE 2015, 10, e0136530. [CrossRef] [PubMed]
6. Morgan, G.; Ward, R.; Barton, M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin. Oncol. J. (R. Coll. Radiol.) 2004, 16, 549-560. [CrossRef]
7. Siddiqui, M.; Rajkumar, S.V. The high cost of cancer drugs and what we can do about it. Mayo Clin. Proc. 2012, 87, 935-943. [CrossRef] [PubMed]
8. Shutava, T.G.; Balkundi, S.S.; Vangala, P.; Steffan, J.J.; Bigelow, R.L.; Cardelli, J.A.; O’Neal, D.P.; Lvov, Y.M. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 2009, 3, 1877-1885. [CrossRef] [PubMed]
9. Nyamai, D.W.; Arika, W.; Ogola, P.E.; Njagi, E.N.M.; Ngugi, M.P. Medicinally Important Phytochemicals: An Untapped Research Avenue. Res. Rev. J. Pharmacogn. Phytochem. 2016, 4, 35-49.
10. Xiao, L.; Mertens, M.; Wortmann, L.; Kremer, S.; Valldor, M.; Lammers, T.; Kiessling, F.; Mathur, S. Enhanced in vitro and in vivo cellular imaging with green tea coated water-soluble iron oxide nanocrystals. ACS Appl. Mater. Interfaces 2015, 7, 6530-6540. [CrossRef] [PubMed]
11. Mukherjee, S.; Ghosh, S.; Das, D.K.; Chakraborty, P.; Choudhury, S.; Gupta, P.; Adhikary, A.; Dey, S.; Chattopadhyay, S. Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and hepatoprotection-Synthesis, characterization and in vitro evaluation. J. Nutr. Biochem. 2015, 26, 1283-1297. [CrossRef] [PubMed]
12. Rahmani, A.H.; Al Shabrmi, F.M.; Allemailem, K.S.; Aly, S.M.; Khan, M.A. Implications of green tea and its constituents in the prevention of cancer via the modulation of cell signalling pathway. BioMed Res. Int. 2015, 2015. [CrossRef] [PubMed]
13. Thangapazham, R.L.; Singh, A.K.; Sharma, A.; Warren, J.; Gaddipati, J.P.; Maheshwari, R.K. Green tea polyphenols and its constituent Epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett. 2007, 245, 232-241. [CrossRef] [PubMed]
14. Xu, Y.; Ho, C.T.; Amin, S.G.; Han, C.; Chung, F.L. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res. 1992, 52, 3875-3879. [PubMed]
15. Ju, J.; Hong, J.; Zhou, J.; Pan, Z.; Bose, M.; Liao, J.; Yang, G.; Liu, Y.Y.; Hou, Z.; Lin, Y.; et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-Epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res. 2005, 65, 10623-10631. [CrossRef] [PubMed]
16. Lu, Y.P.; Lou, Y.R.; Xie, J.G.; Peng, Q.Y.; Liao, J.; Yang, C.S.; Huang, M.T.; Conney, A.H. Topical applications of caffeine or (-)-Epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc. Natl. Acad. Sci. USA 2002, 99, 12455-12460. [CrossRef] [PubMed]
17. Fujiki, H. Two stages of cancer prevention with green tea. J. Cancer Res. Clin. Oncol. 1999, 125, 589-597. [CrossRef] [PubMed]
18. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66, 1234-1240. [CrossRef] [PubMed]
19. Kurahashi, N.; Sasazuki, S.; Iwasaki, M.; Inoue, M.; Tsugane, S. Green tea consumption and prostate cancer risk in Japanese men: A prospective study. Am. J. Epidemiol. 2008, 167, 71-77. [CrossRef] [PubMed]
20. Sasazuki, S.; Inoue, M.; Hanaoka, T.; Yamamoto, S.; Sobue, T.; Tsugane, S. Green tea consumption and subsequent risk of gastric cancer by subsite: The JPHC Study. Cancer Causes Control. 2004, 15, 483-491. [CrossRef] [PubMed]
21. Kang, H.; Rha, S.Y.; Oh, K.W.; Nam, C.M. Green tea consumption and stomach cancer risk: A meta-analysis. Epidemiol. Health 2010, 32, e2010001. [CrossRef] [PubMed]
22. Singh, B.N.; Shankar, S.; Srivastava, R.K. Green tea catechin, Epigallocatechin-3-gallate (EGCG): Mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011, 82, 1807-1821. [CrossRef] [PubMed]
23. De Pace, R.C.C.; Liu, X.; Sun, M.; Nie, S.; Zhang, J.; Cai, Q.; Gao, W.; Pan, X.; Fan, Z.; Wang, S. Anticancer activities of (-)-Epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J. Liposome Res. 2013, 23, 187-196. [CrossRef] [PubMed]
24. Nakagawa, K.; Okuda, S.; Miyazawa, T. Dose-dependent incorporation of tea catechins, (-)-Epigallocatechin-3-gallate and (-)-Epigallocatechin, into human plasma. Biosci. Biotechnol. Biochem. 1997, 61, 1981-1985. [CrossRef] [PubMed]
25. Siddiqui, I.A.; Adhami, V.M.; Bharali, D.J.; Hafeez, B.B.; Asim, M.; Khwaja, S.I.; Ahmad, N.; Cui, H.; Mousa, S.A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol Epigallocatechin-3-gallate. Cancer Res. 2009, 69, 1712-1716. [CrossRef] [PubMed]
26. Yamamoto, T.; Juneja, L.R.; Chu, sDjong-C.; Kim, M. Chemistry and Applications of Green Tea; CRC Press: Boca Raton, FL, USA, 1997.
27. Ahmad, N.; Mukhtar, H. Green tea polyphenols and cancer: Biologic mechanisms and practical implications. Nutr. Rev. 1999, 57, 78-83. [CrossRef] [PubMed]
28. O’Grady, M.N.; Kerry, J.P. Using antioxidants and nutraceuticals as dietary supplements to improve the quality and shelf-life of fresh meat. In Improving the Sensory and Nutritional Quality of Fresh Meat; Woodhead Publishing Limited: Cambridge, UK, 2009; pp. 356-386.
29. Velickovic, T.C.; Gavrovic-Jankulovic, M. Food Allergens: Biochemistry and Molecular Nutrition; Springer: New York, NY, USA, 2014.
30. Nakagawa, T.; Yokozawa, T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem. Toxicol. 2002, 40, 1745-1750. [CrossRef]
31. Ho, C.T.; Chen, Q.; Shi, H.; Zhang, K.Q.; Rosen, R.T. Antioxidative effect of polyphenol extract prepared from various Chinese teas. Prev. Med. (Baltim.) 1992, 21, 520-525. [CrossRef]
32. Betts, J.W.;Wareham, D.W. in vitro activity of curcumin in combination with Epigallocatechin gallate (EGCG) versus multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2014, 14, 172. [CrossRef] [PubMed]
33. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Anti-infective properties of Epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. 2013, 168, 1059-1073. [CrossRef] [PubMed]
34. Huang, H.C.; Tao, M.H.; Hung, T.M.; Chen, J.C.; Lin, Z.J.; Huang, C. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antivir. Res. 2014, 111, 100-111. [CrossRef] [PubMed]
35. Calland, N.; Albecka, A.; Belouzard, S.; Wychowski, C.; Duverlie, G.; Descamps, V.; Hober, D.; Dubuisson, J.; Rouillé, Y.; Séron, K. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012, 55, 720-729. [CrossRef] [PubMed]
36. Weber, C.; Sliva, K.; von Rhein, C.; Kümmerer, B.M.; Schnierle, B.S. The green tea catechin, Epigallocatechin gallate inhibits chikungunya virus infection. Antivir. Res. 2015, 113, 1-3. [CrossRef] [PubMed]
37. Munir, K.M.; Chandrasekaran, S.; Gao, F.; Quon, M.J. Mechanisms for food polyphenols to ameliorate insulin resistance and endothelial dysfunction: Therapeutic implications for diabetes and its cardiovascular complications. Am. J. Physiol. Endocrinol. Metab. 2013, 305, E679-E686. [CrossRef] [PubMed]
38. Babu, P.V.A.; Liu, D.; Gilbert, E.R. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. J. Nutr. Biochem. 2013, 24, 1777-1789. [CrossRef] [PubMed]
39. Iso, H. The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among japanese adults. Ann. Intern. Med. 2006, 144, 554-562. [CrossRef] [PubMed]
40. Panagiotakos, D.B.; Lionis, C.; Zeimbekis, A.; Gelastopoulou, K.; Papairakleous, N.; Das, U.N.; Polychronopoulos, E. Long-term tea intake is associated with reduced prevalence of (type 2) diabetes mellitus among elderly people from Mediterranean islands: MEDIS epidemiological study. Yonsei Med. J. 2009, 50, 31-38. [CrossRef] [PubMed]
41. Khurana, S.; Venkataraman, K.; Hollingsworth, A.; Piche, M.; Tai, T.C. Polyphenols: Benefits to the cardiovascular system in health and in aging. Nutrients 2013, 5, 3779-3827. [CrossRef] [PubMed]
42. Osada, K.; Takahashi, M.; Hoshina, S.; Nakamura, M.; Nakamura, S.; Sugano, M. Tea catechins inhibit cholesterol oxidation accompanying oxidation of low density lipoprotein in vitro. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2001, 128, 153-164. [CrossRef]
43. Kuriyama, S.; Shimazu, T.; Ohmori, K.; Kikuchi, N.; Nakaya, N.; Nishino, Y.; Tsubono, Y.; Tsuji, I. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: The Ohsaki study. JAMA 2006, 296, 1255-1265. [CrossRef] [PubMed]
44. Geleijnse, J.M.; Launer, L.J.; Van der Kuip, D.A.M.; Hofman, A.; Witteman, J.C.M. Inverse association of tea and flavonoid intakes with incident myocardial infarction: The Rotterdam Study. Am. J. Clin. Nutr. 2002, 75, 880-886. [PubMed]
45. Yang, Y.C.; Lu, F.H.; Wu, J.S.; Wu, C.H.; Chang, C.J. The protective effect of habitual tea consumption on hypertension. Arch. Intern. Med. 2004, 164, 1534-1540. [CrossRef] [PubMed]
46. Geleijnse, J.M.; Launer, L.J.; Hofman, A.; Pols, H.A.; Witteman, J.C. Tea flavonoids may protect against atherosclerosis: The Rotterdam Study. Arch. Intern. Med. 1999, 159, 2170-2174. [CrossRef] [PubMed]
47. Diepvens, K.; Westerterp, K.R.; Westerterp-Plantenga, M.S. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 292, R77-R85. [CrossRef] [PubMed]
48. Lim, H.J.; Shim, S.B.; Jee, S.W.; Lee, S.H.; Lim, C.J.; Hong, J.T.; Sheen, Y.Y.; Hwang, D.Y. Green tea catechin leads to global improvement among Alzheimer’s disease-Related phenotypes in NSE/hAPP-C105 Tg mice. J. Nutr. Biochem. 2013, 24, 1302-1313. [CrossRef] [PubMed]
49. Mandel, S.A.; Amit, T.;Weinreb, O.; Youdim, M.B.H. Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis. 2011, 25, 187-208. [PubMed]
50. Rigacci, S.; Stefani, M. Nutraceuticals and amyloid neurodegenerative diseases: A focus on natural phenols. Expert Rev. Neurother. 2015, 15, 41-52. [CrossRef] [PubMed]
51. Ruddon, R.W. Cancer Biology; Oxford University Press: New York, NY, USA, 2007.
52. Mikeska, T.; Craig, J.M. DNAmethylation biomarkers: Cancer and beyond. Genes 2014, 5, 821-864. [CrossRef] [PubMed]
53. Jones, P.A.; Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3, 415-428. [PubMed]
54. Baylin, S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2 (Suppl. 1), S4-S11. [CrossRef] [PubMed]
55. Fang, M.Z.; Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C.S. Tea polyphenol (-)-Epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63, 7563-7570. [PubMed]
56. Gavory, G.; Farrow, M.; Balasubramanian, S. Minimum length requirement of the alignment domain of human telomerase RNA to sustain catalytic activity in vitro. Nucleic Acids Res. 2002, 30, 4470-4480. [CrossRef] [PubMed]
57. Kim, N.W.; Piatyszek, M.A.; Prowse, K.R.; Harley, C.B.;West, M.D.; Ho, P.L.; Coviello, G.M.;Wright,W.E.; Weinrich, S.L.; Shay, J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266, 2011-2015. [CrossRef] [PubMed]
58. Sadava, D.; Whitlock, E.; Kane, S.E. The green tea polyphenol, Epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem. Biophys. Res. Commun. 2007, 360, 233-237. [CrossRef] [PubMed]
59. Yokoyama, M.; Noguchi, M.; Nakao, Y.; Pater, A.; Iwasaka, T. The tea polyphenol, (-)-Epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines. Gynecol. Oncol. 2004, 92, 197-204. [CrossRef] [PubMed]
60. Naasani, I.; Seimiya, H.; Tsuruo, T. Telomerase Inhibition, Telomere Shortening, and Senescence of Cancer Cells by Tea Catechins. Biochem. Biophys. Res. Commun. 1998, 249, 391-396. [CrossRef] [PubMed]
61. Sledge, G.; Miller, K. Exploiting the hallmarks of cancer. Eur. J. Cancer 2003, 39, 1668-1675. [CrossRef]
62. Roudsari, L.C.; West, J.L. Studying the influence of angiogenesis in in vitro cancer model systems. Adv. Drug Deliv. Rev. 2015, 97, 250-259. [CrossRef] [PubMed]
63. Byrne, A.M.; Bouchier-Hayes, D.J.; Harmey, J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell. Mol. Med. 2005, 9, 777-794. [CrossRef] [PubMed]
64. Wang, H.; Bian, S.; Yang, C.S. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α. Carcinogenesis 2011, 32, 1881-1889. [CrossRef] [PubMed]
65. Gu, J.-W.; Makey, K.L.; Tucker, K.B.; Chinchar, E.; Mao, X.; Pei, I.; Thomas, E.Y.; Miele, L. EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression. Vasc. Cell 2013, 5, 9. [CrossRef] [PubMed]
66. Li, X.; Feng, Y.; Liu, J.; Feng, X.; Zhou, K.; Tang, X. Epigallocatechin-3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1α and VEGF expression. J. Nutr. Nutr. 2013, 6, 169-178.
67. Shankar, S.; Ganapathy, S.; Hingorani, S.R.; Srivastava, R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front. Biosci. 2008, 13, 440-452. [CrossRef] [PubMed]
68. Isemura, M.; Saeki, K.; Kimura, T.; Hayakawa, S.; Minami, T.; Sazuka, M. Tea catechins and related polyphenols as anti-cancer agents. Biofactors 2000, 13, 81-85. [CrossRef] [PubMed]
69. Garbisa, S.; Biggin, S.; Cavallarin, N.; Sartor, L.; Benelli, R.; Albini, A. Tumor invasion: Molecular shears blunted by green tea. Nat. Med. 1999, 5, 1216. [CrossRef] [PubMed]
70. Demeule, M.; Brossard, M.; Pagé, M.; Gingras, D.; Béliveau, R. Matrix metalloproteinase inhibition by green tea catechins. Biochim. Biophys. Acta 2000, 1478, 51-60. [CrossRef]
71. Zhen, M.; Huang, X.;Wang, Q.; Sun, K.; Liu, Y.; Li,W.; Zhang, L.; Cao, L.; Chen, X. Green tea polyphenol Epigallocatechin-3-gallate suppresses rat hepatic stellate cell invasion by inhibition of MMP-2 expression and its activation. Acta Pharmacol. Sin. 2006, 27, 1600-1607. [CrossRef] [PubMed]
72. Koff, J.; Ramachandiran, S.; Bernal-Mizrachi, L. A Time to Kill: Targeting Apoptosis in Cancer. Int. J. Mol. Sci. 2015, 16, 2942-2955. [CrossRef] [PubMed]
73. Shankar, S.; Suthakar, G.; Srivastava, R.K. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front. Biosci. 2007, 12, 5039-5051. [CrossRef] [PubMed]
74. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J.C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003, 63, 8118-8121. [PubMed]
75. Sonoda, J.I.; Ikeda, R.; Baba, Y.; Narumi, K.; Kawachi, A.; Tomishige, E.; Nishihara, K.; Takeda, Y.; Yamada, K.; Sato, K.; et al. Green tea catechin, Epigallocatechin-3-gallate, attenuates the cell viability of human non-small-cell lung cancer A549 cells via reducing Bcl-xL expression. Exp. Ther. Med. 2014, 8, 59-63. [CrossRef] [PubMed]
76. Yang, W.H.; Fong, Y.C.; Lee, C.Y.; Jin, T.R.; Tzen, J.T.; Li, T.M.; Tang, C.H. Epigallocatechin-3-gallate induces cell apoptosis of human chondrosarcoma cells through apoptosis signal-regulating kinase 1 pathway. J. Cell. Biochem. 2011, 112, 1601-1611. [CrossRef] [PubMed]
77. 2) production in transformed and non-transformed human bronchial cell lines: Possible mechanisms of cell growth inhibition and apoptosis induction. Carcinogenesis 2000, 21, 2035-2039. [CrossRef] [PubMed]
78. Ahmad, N.; Cheng, P.; Mukhtar, H. Cell cycle dysregulation by green tea polyphenol Epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 2000, 275, 328-334. [CrossRef] [PubMed]
79. Fatemi, A.; Safa, M.; Kazemi, A. MST-312 induces G2/M cell cycle arrest and apoptosis in APL cells through inhibition of telomerase activity and suppression of NF-κB pathway. Tumour Biol. 2015, 36, 8425-8437. [CrossRef] [PubMed]
80. Singh, M.; Singh, R.; Bhui, K.; Tyagi, S.; Mahmood, Z.; Shukla, Y. Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor-kappaB and Akt activation in human cervical cancer cells. Oncol. Res. 2011, 19, 245-257. [CrossRef] [PubMed]
81. Polinsky, K.R. Tumor Suppressor Genes; Nova Publishers: Hauppauge, NY, USA, 2007.
82. Thakur, V.S.; Gupta, K.; Gupta, S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int. J. Oncol. 2012, 41, 353-361. [PubMed]
83. Hastak, K.; Agarwal, M.K.; Mukhtar, H.; Agarwal, M.L. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol Epigallocatechin-3-gallate. FASEB J. 2005, 19, 789-791. [CrossRef] [PubMed]
84. Liu, S.; Wang, X.J.; Liu, Y.; Cui, Y.F. PI3K/AKT/mTOR signaling is involved in (-)-Epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. Am. J. Chin. Med. 2013, 41, 629-642. [CrossRef] [PubMed]
85. Liang, Y.C.; Lin-Shiau, S.Y.; Chen, C.F.; Lin, J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-Epigallocatechin-3-gallate. J. Cell. Biochem. 1999, 75, 1-12. [CrossRef]
86. Ozols, R.F. Ovarian Cancer; BC Decker Inc: Hamilton, ON, Canada, 2003; Volume 1.
87. Iqbal, N.; Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol. Biol. Int. 2014. [CrossRef] [PubMed]
88. Milanezi, F.; Carvalho, S.; Schmitt, F.C. EGFR/HER2 in breast cancer: A biological approach for molecular diagnosis and therapy. Expert Rev. Mol. Diagn. 2008, 8, 417-434. [CrossRef] [PubMed]
89. Ma, Y.C.; Li, C.; Gao, F.; Xu, Y.; Jiang, Z.B.; Liu, J.X.; Jin, L.Y. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. Oncol. Rep. 2014, 31, 1343-1349. [PubMed]
90. Lim, Y.C.; Cha, Y.Y. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. J. Surg. Oncol. 2011, 104, 776-780. [CrossRef] [PubMed]
91. Masuda, M.; Suzui, M.; Lim, J.T.E.;Weinstein, I.B. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin. Cancer Res. 2003, 9, 3486-3491. [PubMed]
92. Pianetti, S.; Guo, S.; Kavanagh, K.T.; Sonenshein, G.E. Green tea polyphenol Epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 2002, 62, 652-655. [PubMed]
93. Aggarwal, B.B.; Shishodia, S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71, 1397-1421. [CrossRef] [PubMed]
94. Ahmad, N.; Gupta, S.; Mukhtar, H. Green tea polyphenol Epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch. Biochem. Biophys. 2000, 376, 338-346. [CrossRef] [PubMed]
95. Qin, J.;Wang, Y.; Bai, Y.; Yang, K.; Mao, Q.; Lin, Y.; Kong, D.; Zheng, X.; Xie, L. Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Mol. Med. Rep. 2012, 6, 1040-1044. [PubMed]
96. Masuda, M.; Suzui, M.; Lim, J.T.E.; Deguchi, A.; Soh, J.W.;Weinstein, I.B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350-359. [CrossRef] [PubMed]
97. Seger, R.; Krebs, E.G. The MAPK signaling cascade. FASEB J. 1995, 9, 726-735. [PubMed]
98. Cerezo-Guisado, M.I.; Zur, R.; Lorenzo, M.J.; Risco, A.; Martín-Serrano, M.A.; Alvarez-Barrientos, A.; Cuenda, A.; Centeno, F. Implication of Akt, ERK1/2 and alternative p38MAPK signalling pathways in human colon cancer cell apoptosis induced by green tea EGCG. Food Chem. Toxicol. 2015, 84, 125-132. [CrossRef] [PubMed]
99. Park, S.B.; Bae, J.W.; Kim, J.M.; Lee, S.G.; Han, M. Antiproliferative and apoptotic effect of Epigallocatechin-3-gallate on Ishikawa cells is accompanied by sex steroid receptor downregulation. Int. J. Mol. Med. 2012, 30, 1211-1218. [PubMed]
100. Ly, B.T.K.; Chi, H.T.; Yamagishi, M.; Kano, Y.; Hara, Y.; Nakano, K.; Sato, Y.; Watanabe, T. Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells. PLoS ONE 2013, 8, e66378. [CrossRef] [PubMed]
101. Adhami, V.M.; Siddiqui, I.A.; Ahmad, N.; Gupta, S.; Mukhtar, H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004, 64, 8715-8522. [CrossRef] [PubMed]
102. Li, M.; He, Z.; Ermakova, S.; Zheng, D.; Tang, F.; Cho, Y.Y.; Zhu, F.; Ma,W.Y.; Sham, Y.; Rogozin, E.A.; et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-Epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol. Biomark. Prev. 2007, 16, 598-605. [CrossRef] [PubMed]
103. Sazuka, M.; Itoi, T.; Suzuki, Y.; Odani, S.; Koide, T.; Isemura, M. Evidence for the interaction between (-)-Epigallocatechin gallate and human plasma proteins fibronectin, fibrinogen, and histidine-rich glycoprotein. Biosci. Biotechnol. Biochem. 1996, 60, 1317-1319. [CrossRef] [PubMed]
104. Suzuki, Y.; Isemura, M. Inhibitory effect of Epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett. 2001, 173, 15-20. [CrossRef]
105. Suzuki, Y.; Isemura, M. Binding interaction between (-)-Epigallocatechin gallate causes impaired spreading of cancer cells on fibrinogen. Biomed. Res. 2013, 34, 301-308. [CrossRef] [PubMed]
106. Hayakawa, S.; Saeki, K.; Sazuka, M.; Suzuki, Y.; Shoji, Y.; Ohta, T.; Kaji, K.; Yuo, A.; Isemura, M. Apoptosis induction by Epigallocatechin gallate involves its binding to Fas. Biochem. Biophys. Res. Commun. 2001, 285, 1102-1106. [CrossRef] [PubMed]
107. Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. A receptor for green tea polyphenol EGCG. Nat. Struct. Mol. Biol. 2004, 11, 380-381. [CrossRef] [PubMed]
108. Ermakova, S.; Choi, B.Y.; Choi, H.S.; Kang, B.S.; Bode, A.M.; Dong, Z. The intermediate filament protein vimentin is a new target for Epigallocatechin gallate. J. Biol. Chem. 2005, 280, 16882-16890. [CrossRef] [PubMed]
109. Ermakova, S.P.; Kang, B.S.; Choi, B.Y.; Choi, H.S.; Schuster, T.F.; Ma, W.Y.; Bode, A.M.; Dong, Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006, 66, 9260-9269. [CrossRef] [PubMed]
110. He, Z.; Tang, F.; Ermakova, S.; Li, M.; Zhao, Q.; Cho, Y.Y.; Ma, W.Y.; Choi, H.S.; Bode, A.M.; Yang, C.S.; et al. Fyn is a novel target of (-)-Epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol. Carcinog. 2008, 47, 172-183. [CrossRef] [PubMed]
111. Shim, J.H.; Choi, H.S.; Pugliese, A.; Lee, S.Y.; Chae, J.I.; Choi, B.Y.; Bode, A.M.; Dong, Z. (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J. Biol. Chem. 2008, 283, 28370-28379. [CrossRef] [PubMed]
112. Shim, J.H.; Su, Z.Y.; Chae, J.I.; Kim, D.J.; Zhu, F.; Ma, W.Y.; Bode, A.M.; Yang, C.S.; Dong, Z. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev. Res. (Phila.) 2010, 3, 670-679. [CrossRef] [PubMed]
113. Urusova, D.V.; Shim, J.H.; Kim, D.J.; Jung, S.K.; Zykova, T.A.; Carper, A.; Bode, A.M.; Dong, Z. Epigallocatechin-gallate suppresses tumorigenesis by directly targeting Pin1. Cancer Prev. Res. (Phila.) 2011, 4, 1366-1377. [CrossRef] [PubMed]
114. Liao, S.; Umekita, Y.; Guo, J.; Kokontis, J.M.; Hiipakka, R.A. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea Epigallocatechin gallate. Cancer Lett. 1995, 96, 239-243. [CrossRef]
115. Ahn, W.S.; Yoo, J.; Huh, S.W.; Kim, C.K.; Lee, J.M.; Namkoong, S.E.; Bae, S.M.; Lee, I.P. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. 2003, 12, 383-390. [CrossRef] [PubMed]
116. McLarty, J.; Bigelow, R.L.H.; Smith, M.; Elmajian, D.; Ankem, M.; Cardelli, J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res. (Phila.) 2009, 2, 673-682. [PubMed]
117. Jatoi, A.; Ellison, N.; Burch, P.A.; Sloan, J.A.; Dakhil, S.R.; Novotny, P.; Tan,W.; Fitch, T.R.; Rowland, K.M.; Young, C.Y.F.; et al. phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97, 1442-1446. [CrossRef] [PubMed]
118. Zhou, Y.; Li, N.; Zhuang,W.; Liu, G.;Wu, T.; Yao, X.; Du, L.;Wei, M.; Wu, X. Green tea and gastric cancer risk: Meta-analysis of epidemiologic studies. Asia Pac. J. Clin. Nutr. 2008, 17, 159-165. [PubMed]
119. Lin, Y.; Kikuchi, S.; Tamakoshi, A.; Yagyu, K.; Obata, Y.; Kurosawa, M.; Inaba, Y.; Kawamura, T.; Motohashi, Y.; Ishibashi, T. Green tea consumption and the risk of pancreatic cancer in Japanese adults. Pancreas 2008, 37, 25-30. [CrossRef] [PubMed]
120. Sasazuki, S.; Tamakoshi, A.; Matsuo, K.; Ito, H.; Wakai, K.; Nagata, C.; Mizoue, T.; Tanaka, K.; Tsuji, I.; Inoue, M.; et al. Green tea consumption and gastric cancer risk: An evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn. J. Clin. Oncol. 2012, 42, 335-346. [CrossRef] [PubMed]
121. Wang, H.; Zhou, H.; Yang, C.S. Cancer prevention with green tea polyphenols. In Cancer Chemoprevention and Treatment by Diet Therapy; Springer: Dordrecht, The Netherlands, 2013; pp. 91-119.
122. Selvamuthukumar, S.; Velmurugan, R. Nanostructured lipid carriers: A potential drug carrier for cancer chemotherapy. Lipids Health Dis. 2012, 11, 159. [CrossRef] [PubMed]
123. Lecumberri, E.; Dupertuis, Y.M.; Miralbell, R.; Pichard, C. Green tea polyphenol Epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin. Nutr. 2013, 32, 894-903. [CrossRef] [PubMed]
124. Siddiqui, I.A.; Adhami, V.M.; Ahmad, N.; Mukhtar, H. Nanochemoprevention: Sustained release of bioactive food components for cancer prevention. Nutr. Cancer 2010, 62, 883-890. [CrossRef] [PubMed]
125. Chen, C.C.; Hsieh, D.S.; Huang, K.J.; Chan, Y.L.; Hong, P.D.; Yeh, M.K.; Wu, C.J. Improving anticancer efficacy of (-)-Epigallocatechin-3-gallate gold nanoparticles in murine B16F10 melanoma cells. Drug Des. Dev. Ther. 2014, 8, 459-473.
126. Khan, N.; Bharali, D.J.; Adhami, V.M.; Siddiqui, I.A.; Cui, H.; Shabana, S.M.; Mousa, S.A.; Mukhtar, H. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2014, 35, 415-423. [CrossRef] [PubMed]
127. Jain, S.; Hirst, D.G.; O’Sullivan, J.M. Gold nanoparticles as novel agents for cancer therapy. Br. J. Radiol. 2012, 85, 101-113. [CrossRef] [PubMed]
128. Nune, S.K.; Chanda, N.; Shukla, R.; Katti, K.; Kulkarni, R.R.; Thilakavathy, S.; Mekapothula, S.; Kannan, R.; Katti, K.V. Green nanotechnology from tea: Phytochemicals in tea as building blocks for production of biocompatible gold nanoparticles. J. Mater. Chem. 2009, 19, 2912. [CrossRef] [PubMed]
129. Nie, L.; Liu, F.; Ma, P.; Xiao, X. Applications of gold nanoparticles in optical biosensors. J. Biomed. Nanotechnol. 2014, 10, 2700-2721. [CrossRef] [PubMed]
130. Hsieh, D.S.; Wang, H.; Tan, S.W.; Huang, Y.H.; Tsai, C.Y.; Yeh, M.K.; Wu, C.J. The treatment of bladder cancer in a mouse model by Epigallocatechin-3-gallate-gold nanoparticles. Biomaterials 2011, 32, 7633-7640. [CrossRef] [PubMed]
131. Sanna, V.; Pala, N.; Dessi, G.; Manconi, P.; Mariani, A.; Dedola, S.; Rassu, M.; Crosio, C.; Iaccarino, C.; Sechi, M. Single-step green synthesis and characterization of gold-conjugated polyphenol nanoparticles with antioxidant and biological activities. Int. J. Nanomedicine 2014, 9, 4935-4951. [PubMed]
132. Alotaibi, A.; Bhatnagar, P.; Najafzadeh, M.; Gupta, K.C.; Anderson, D. Tea phenols in bulk and nanoparticle form modify DNA damage in human lymphocytes from colon cancer patients and healthy individuals treated in vitro with platinum based-chemotherapeutic drugs. Nanomedicine (Lond.) 2013, 8, 389-401. [CrossRef] [PubMed]
133. Elsabahy, M.; Wooley, K.L. Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev. 2012, 41, 2545-2561. [CrossRef] [PubMed]
134. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B. Biointerfaces 2010, 75, 1-18. [CrossRef] [PubMed]
135. Sanna, V.; Pintus, G.; Roggio, A.M.; Punzoni, S.; Posadino, A.M.; Arca, A.; Marceddu, S.; Bandiera, P.; Uzzau, S.; Sechi, M. Targeted biocompatible nanoparticles for the delivery of (-)-Epigallocatechin 3-gallate to prostate cancer cells. J. Med. Chem. 2011, 54, 1321-1332. [CrossRef] [PubMed]
136. Narayanan, S.; Pavithran, M.; Viswanath, A.; Narayanan, D.; Mohan, C.C.; Manzoor, K.; Menon, D. Sequentially releasing dual-drug-loaded PLGA-casein core/shell nanomedicine: Design, synthesis, biocompatibility and pharmacokinetics. Acta Biomater. 2014, 10, 2112-2124. [CrossRef] [PubMed]
137. Narayanan, S.; Mony, U.; Vijaykumar, D.K.; Koyakutty, M.; Paul-Prasanth, B.; Menon, D. Sequential release of Epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells. Nanomedicine 2015, 11, 1399-1406. [CrossRef] [PubMed]
138. Siddiqui, I.A.; Bharali, D.J.; Nihal, M.; Adhami, V.M.; Khan, N.; Chamcheu, J.C.; Khan, M.I.; Shabana, S.; Mousa, S.A.; Mukhtar, H. Excellent anti-proliferative and pro-apoptotic effects of (-)-Epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomedicine 2014, 10, 1619-1626. [CrossRef] [PubMed]
139. Hu, B.; Xie, M.; Zhang, C.; Zeng, X. Genipin-structured peptide-polysaccharide nanoparticles with significantly improved resistance to harsh gastrointestinal environments and their potential for oral delivery of polyphenols. J. Agric. Food Chem. 2014, 62, 12443-12452. [CrossRef] [PubMed]
140. Fang, J.Y.; Lee, W.R.; Shen, S.C.; Huang, Y.L. Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J. Dermatol. Sci. 2006, 42, 101-109. [CrossRef] [PubMed]
141. Ramadass, S.K.; Anantharaman, N.V.; Subramanian, S.; Sivasubramanian, S.; Madhan, B. Paclitaxel/Epigallocatechin gallate coloaded liposome: A synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells. Colloids Surf. B Biointerfaces 2015, 125, 65-72. [CrossRef] [PubMed]
142. Fang, J.Y.; Hung, C.F.; Hwang, T.L.; Huang, Y.L. Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J. Drug Target. 2005, 13, 19-27. [CrossRef] [PubMed]
143. Rocha, S.; Generalov, R.; Peres, I.; Juzenas, P. Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine (Lond.) 2011, 6, 79-87. [CrossRef] [PubMed]
144. Zhou, Y.; Yu, Q.; Qin, X.; Bhavsar, D.; Yang, L.; Chen, Q.; Zheng,W.; Chen, L.; Liu, J. Improving the Anticancer Efficacy of Laminin Receptor-Specific Therapeutic Ruthenium Nanoparticles (RuBB-Loaded EGCG-RuNPs) via ROS-Dependent Apoptosis in SMMC-7721 Cells. ACS Appl. Mater. Interfaces 2015. [CrossRef] [PubMed]
145. Janeiro, P.; Oliveira Brett, A.M. Catechin electrochemical oxidation mechanisms. Anal. Chim. Acta 2004, 518, 109-115. [CrossRef]
146. Dube, A.; Ng, K.; Nicolazzo, J.A.; Larson, I. Effective use of reducing agents and nanoparticle encapsulation in stabilizing catechins in alkaline solution. Food Chem. 2010, 122, 662-667. [CrossRef]